Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07073547 · ClinicalTrials.gov registry record · Phase 1
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
A Phase 1 study of Multiple Myeloma, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 13
- Study locations
NCT07073547: Recruiting Phase 1 study of Multiple Myeloma, sponsored by AstraZeneca.
NCT07073547 is a Phase 1 study of Multiple Myeloma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 40 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (93% lower). The trial reports 13 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07073547, a Phase 1 study of Multiple Myeloma, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is an interventional, modular, open-label, multicenter study to primarily evaluate the safety and tolerability of AZD0120 in adult participants with multiple myeloma (MM).
Primary Outcome
Incidence and severity of adverse events (AEs)
Conditions Studied
Interventions
- BIOLOGICAL AZD0120
Study Locations (13)
Texas
- Research Site - Dallas
- Research Site - Houston
Arizona
- Research Site - Phoenix
California
- Research Site - Duarte
Colorado
- Research Site - Denver
Florida
- Research Site - Tampa
Georgia
- Research Site - Atlanta
Iowa
- Research Site - Iowa City
Minnesota
- Research Site - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-07-31 |
| Est. Completion | 2028-05-26 |
| Phase | Phase 1 |
What NCT07073547 shows while recruiting
NCT07073547 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which AZD0120 is the first listed.
NCT07073547 lists 13 locations in 12 states (Texas, Arizona, California).
Frequently Asked Questions
What is clinical trial NCT07073547 about?
NCT07073547 is a clinical study titled "A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)". This is an interventional, modular, open-label, multicenter study to primarily evaluate the safety and tolerability of AZD0120 in adult participants with multiple myeloma (MM).
What is the current status of trial NCT07073547?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2025-07-31. Estimated completion is 2028-05-26.
What conditions does trial NCT07073547 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT07073547?
The interventions under investigation include: AZD0120 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07073547?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07073547 being conducted?
This trial has 13 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07073547's enrollment target sits among peer trials
40 289th of 438 higher than 135 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI